Reducing Relapse in Depressed Outpatients with Atypical Features: A Pilot Study

Jarrett, Robin B.; Kraft, Dolores; Schäffer, Michael; Witt-Browder, Amy; Risser, Richard C.; Atkins, Deborah H.; Doyle, Jeanette

doi:10.1159/000012401

Cited by 42 publications

(26 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As shown in a review by Hardeveld et al [9], rates of relapse/recurrence and long term effectiveness of psychiatric treatment vary, but a relapse/recurrence rate of 61 % must still be considered high. However examples of similar relapse/recurrence rates have been reported in several out-patient settings among samples discontinuing antidepressant medication [5,19,20].…”

Section: Status Of Depression At 12-month Follow-upmentioning

confidence: 52%

12-Month Outcome and Predictors of Recurrence in Psychiatric Treatment of Depression: A Retrospective Study

2015

View full text Add to dashboard Cite

Many individuals treated for depression suffer relapse or recurrence after treatment. Known risk factors include number of previous depressive episodes and residual symptoms after treatment. Both relapse/recurrence rates and predictors of relapse/recurrence, however, may differ between various settings. To perform a naturalistic evaluation of the sustained effectiveness of treatment for adult clinical depression in a psychiatric out-patient setting and to examine psychosocial and clinical predictors of relapse/recurrence. 51 individuals, who were successfully treated/discharged from psychiatric care 12 months prior, were assessed regarding current depressive status and regarding relapse and recurrence. Logistic regression was used to assess the predictive impact of the variables measured. At the 12-month follow-up, 26 % of the participants were in complete remission, 45 % were in partial remission, and 29 % were clinically depressed. In 1 year, 61 % suffered a new depressive episode. Having a greater number of previous episodes and having no partner significantly increased the risk of relapse or recurrence. A high prevalence of depression and partially remitted depression is reported at 12-month follow up, and a large proportion of the sample would likely benefit from active treatment. Relapse/recurrence rates are higher in this study than in many other studies, and it may be hypothesized that they are generally higher in psychiatric settings than in primary care. If so, this would indicate the need for a different treatment strategy in the psychiatric care of depression, with emphasis on long-term management of depression.

show abstract

Section: Status Of Depression At 12-month Follow-upmentioning

confidence: 52%

12-Month Outcome and Predictors of Recurrence in Psychiatric Treatment of Depression: A Retrospective Study

2015

View full text Add to dashboard Cite

show abstract

“…Conversely, the occurrence of relapse in some patients in both active drug groups, 20 mg daily and 90 mg once weekly, and response by many to an increase in dose to 40 mg daily or 90 mg twice weekly indicates the need to evaluate whether a given dose provides optimal coverage for such patients. In light of the substantial proportion (34%) of patients who either did not respond or initially responded but again relapsed within 6 months after the augmentation of medication, other strategies such as switching to another antidepressant, adding another agent [11], or adding cognitive behavioral therapy [12]may be appropriate in some cases. However these switching and augmentation strategies, while studied extensively in the treatment of resistant depression [13, 14], have not been studied at all in the treatment of relapse during continued antidepressant treatment.…”

Section: Discussionmentioning

confidence: 99%

Treatment Approaches to Major Depressive Disorder Relapse

Schmidt

Fava

Zhang

et al. 2002

Psychother Psychosom

View full text Add to dashboard Cite

Objective: Although continuing antidepressant treatment after patients have responded to medication has been shown to greatly reduce the risk of relapse, this risk is not eliminated. A number of theories have been proposed to account for this apparent loss of efficacy. A common initial approach to managing relapse is to increase the dose of antidepressant. We prospectively evaluated the likelihood of response to increasing the fluoxetine doses in patients relapsing during a long-term efficacy study of two fluoxetine dosing regimens. Method: Patients meeting the DSM-IV criteria for major depressive disorder with modified HAMD17 scores ≧18 and CGI-severity scores ≧4 were treated for 13 weeks with open-label 20 mg/day fluoxetine in a multicenter US study. Responders (n = 501) were randomized to 20 mg fluoxetine daily, placebo, or 90 mg enteric-coated fluoxetine weekly for 25 weeks of double-blind continuation treatment. If the patients relapsed during the continuation phase, they were offered a 25-week optional rescue treatment phase during which the study medication dose was increased as follows: (1) patients on placebo had treatment with fluoxetine 20 mg/day reinitiated, (2) patients on fluoxetine 20 mg/day had their dose increased to 40 mg/day, and (3) patients on a 90-mg weekly dose had their dose increased to 90 mg twice a week. The results of the rescue phase for the latter two groups who relapsed while on continuation treatment with fluoxetine are reported. Response was defined as a 50% reduction in the modified HAMD17 score since time of relapse and a CGI-severity score ≤2. Additional efficacy analyses included HAMD and CGI-severity changes from baseline to endpoint. Safety measures included assessment of treatment-emergent adverse events, vital signs, and laboratory measures. Results: Overall, patients relapsing during the continuation treatment responded to an increased dose (57% of the 40-mg-daily group and 72% of the enteric-coated 90-mg-twice-weekly group). Mean modified HAMD17 scores decreased from a mean of approximately 20 to below 8 and were maintained for up to 6 months in the responders. Thirty-five percent of patients either did not respond or initially responded but again relapsed after augmentation of medication. Conclusions: The patients relapsing after initially responding to fluoxetine can benefit from an increase in fluoxetine dose. These results also generally support increasing dose as a first-line treatment strategy for a patient who has relapsed while taking a previously effective dose of an antidepressant. Increasing enteric-coated fluoxetine 90 mg once weekly to twice weekly appeared to be as well-tolerated and effective in restoring response as increasing a daily fluoxetine dose from 20 to 40 mg.

show abstract

“…Alternatively, one could hypothesize that a sensitization phenomenon may have occurred, with the development of tolerance to the effect of the antidepressant [16]. In light of the substantial proportion of patients who either did not respond or initially responded but again relapsed within 6 months after reinitiation of medication, other strategies such as switching to another antidepressant [17], adding another agent [18], or adding cognitive behavioral therapy [19, 20]may be appropriate in some cases. However, these switching and augmentation strategies, while studied extensively in the treatment of resistant depression [17, 18], have not been studied at all in the treatment of relapse upon discontinuation of antidepressant treatment.…”

Section: Discussionmentioning

confidence: 99%

Treatment Approaches to Major Depressive Disorder Relapse

Fava

Schmidt

Zhang

et al. 2002

Psychother Psychosom

View full text Add to dashboard Cite

Background: Anecdotal reports concerning mood disorder patients suggest restarting drug treatment in patients who prematurely discontinue it may be associated with a diminished chance of response upon rechallenge. We evaluated the likelihood of response to reinitiation of fluoxetine treatment in patients relapsing after switching to placebo during a long-term efficacy study of two different dosing regimens of fluoxetine. Method: Patients who met the DSM-IV major depressive disorder criteria with modified HAMD17 scores ≧18 and CGI-Severity scores ≧4 were treated with open-label 20 mg/day fluoxetine for 13 weeks in a multicenter US study. Responders (n = 501) were randomized to placebo, 20 mg fluoxetine daily, or 90 mg enteric-coated fluoxetine weekly for 25 weeks of double-blind continuation treatment. Patients relapsing during the continuation phase were offered 25 weeks of double-blind rescue treatment during which the study medication dose was increased as follows: (1) patients on placebo had treatment with fluoxetine 20 mg/ day reinitiated; (2) patients on fluoxetine 20 mg/day had their dose increased to 40 mg/day, and (3) patients on a 90-mg weekly dose had their dose increased to 90 mg twice a week. Only the results of the rescue phase for the group who relapsed while on continuation treatment with placebo are reported here. Analyses included percentage of responders (50% reduction of modified HAMD17 and CGI-Severity ≤2) and assessments of change from baseline to endpoint (HAMD, CGI-Severity). Safety measures included assessment of vital signs, laboratory measures, and treatment-emergent adverse events. Results: Of 122 patients assigned to placebo, 57 (47%) relapsed during continuation treatment. Fifty-five (96%) of these elected to enter double-blind rescue treatment. Overall, patients who relapsed upon switching to placebo responded well to reinitiation of fluoxetine (62%). The mean modified HAMD17 score decreased from 20 to less than 9 and was maintained for up to 6 months. Thirty-eight percent of patients either did not respond or initially responded but again relapsed after reinitiation of medication. Conclusion: This study suggests that patients who, after an initial response to fluoxetine, relapse upon switching to placebo have a relatively high probability of responding to the reinitiation of fluoxetine treatment. These results challenge the view that the efficacy of an agent prematurely discontinued is diminished when such an agent is restarted. They also generally support reinitiation of the same antidepressant as a ‘first-line’ treatment strategy in patients who relapsed after stopping a previously effective antidepressant.

show abstract

Reducing Relapse in Depressed Outpatients with Atypical Features: A Pilot Study

Cited by 42 publications

References 19 publications

12-Month Outcome and Predictors of Recurrence in Psychiatric Treatment of Depression: A Retrospective Study

12-Month Outcome and Predictors of Recurrence in Psychiatric Treatment of Depression: A Retrospective Study

Treatment Approaches to Major Depressive Disorder Relapse

Treatment Approaches to Major Depressive Disorder Relapse

Contact Info

Product

Resources

About